Table 1.
Characteristics of the study cohort at the time of analysis and last follow-up.
| Control (n=31) | MBL (n=62) | CLL Binet A (n=56) | |
|---|---|---|---|
|
| |||
| Age | 64 (42–88) | 69 (45–89) | 64 (37–89) |
| Absolute lymphocyte count (×109 cells/l) | 1.7 (0.4–3.2) | 5.0 (0.9–10.1) | 13.2 (7.9–24.2) |
| Clonal B cell count (×109 cells/l) | NA* | 2.1 (0.5–4.8) | 10.2 (5.8–19.4) |
| Rai stage | |||
| 0 | NA | NA | 48 (85.7%) |
| I | 8 (14.3%) | ||
| Mutated IGHV | NA | 48/54 (88.9%) | 32/54 (59.3%) |
| Treated patients | NA | 0 | 11 (19.6%) |
| Deaths | NA | 3 (4.8%) | 6 (10.7%) |
| Follow-up from recruitment (months) | NA | 48 (0–117) | 67 (0–143) |
Values are given as median (range) or number (%). NA: not applicable.
*
Polyclonal B cell count: 0.07×109 cells/l (0.04–0.21).